Stephens initiated coverage on NASDAQ:VERX with an "Overweight" rating, signaling a positive future outlook despite recent setbacks.Vertex faces significant challenges due to trial failures in its drug pipeline, notably in acute pain, diabetes, and neuropathic pain treatments.Despite these hurdles, strong sales from cystic fibrosis (CF) therapies and potential from new product launches suggest room for future growth.Vertex Pharmaceuticals, trading under the symbol NASDAQ:VERX, is a prominent player in the b ...